Financial Performance - The basic earnings per share for 2024 is 1.9700 yuan, a decrease of 22.13% compared to 2023's 2.5300 yuan [1] - The net profit for 2024 is 0.99 billion yuan, down 15.38% from 1.17 billion yuan in 2023 [1] - The return on equity (ROE) for 2024 is 4.93%, a significant decline of 46.06% from 9.14% in 2023 [1] - The total revenue for 2024 is 3.36 billion yuan, a decrease of 6.93% from 3.61 billion yuan in 2023 [1] - The net asset per share is 35.57 yuan, down 12.75% from 40.77 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 764.16 million shares, accounting for 29.99% of the circulating shares, with an increase of 187.62 million shares compared to the previous period [1] - China Pharmaceutical Investment Co., Ltd. has newly entered the top shareholders with 194.78 million shares, representing 7.65% of the total share capital [2] - Suzhou Jinhui Phase II Equity Investment Partnership holds 153.75 million shares, a 76.51% increase [2] - Shanghai Hongfu Private Fund Management Co., Ltd. remains unchanged with 138.31 million shares [2] - Shanghai Guanyu Investment Development Co., Ltd. has exited the top ten shareholders, previously holding 44.74 million shares [2] Dividend Distribution - The company has announced a dividend distribution plan of 10 yuan per share (including tax) [3]
西山科技:2024年报净利润0.99亿 同比下降15.38%